Why Tempus AI (TEM) is up 12.4% after announcing its pan-cancer HRD-RNA algorithm

• Earlier this month, Tempus AI announced a new HRD-RNA algorithm for research. The algorithm is an AI-driven 1,660-gene model designed to better identify homologous recombination deficiencies and potential responders to platinum chemotherapy or PARP inhibitors across solid tumors and is expected to be clinically available in late 2026.
• While RNA-based functional approaches have the potential to widen the pool of patients eligible for targeted therapy compared to traditional DNA “genomic scar” testing, Tempus is also deepening its imaging footprint by integrating Median Technologies’ FDA-cleared eyonis LCS lung cancer screening software into the Tempus Pixel platform.
• Next, we consider how the launch of Tempus’ pan-cancer HRD-RNA algorithm could reshape the company’s AI biomarker investment narrative.

We’ve uncovered 15 dividend fortresses yielding 5% or higher that will not only withstand market storms, but thrive during them.

Tempus AI Investment Story Summary

To own Tempus AI, you must believe that its oncology data and AI platform can turn technological breakthroughs into reimbursed tests and recurring software revenue, despite continued losses and hefty valuations. The launch of pan-cancer HRD RNA strengthens the near-term narrative around differentiated biomarkers, but while key near-term catalysts remain in clinical adoption and reimbursement execution, the biggest risk remains that high R&D and AI spending outpaces revenue advances, slowing the path to sustainable cash generation.

The partnership with Median Technologies to bring the FDA-cleared eyonis LCS to the Tempus Pixel platform is particularly relevant here as Tempus highlights how it combines image-based AI with novel biomarkers such as HRD RNA. Taken together, these announcements speak directly to the factors driving the expansion of high-margin software and algorithm offerings in addition to the wet lab business, but they also highlight the risk that reimbursement for AI-based “dry lab” services may prove slower or less favorable than optimists expect.

But investors should also consider how much Tempus’ rich sales multiples amplify risk if redemptions of these AI-powered tools occur…

Read the full story on Tempus AI (it’s free!)

The Tempus AI story projects $2.1 billion in revenue and $295 million in revenue by 2028. This would require annual revenue growth of 29.7%, or an increase in revenue of approximately $495 million from the current -$199.7 million.

We reveal how Tempus AI’s predictions resulted in a fair value of $87.92, which is 51% higher than the current price.

explore other perspectives

The consensus is for annual sales growth of 20%, but the most optimistic analysts model sales of approximately US$2.5b and profits of US$139m by 2029, indicating that assumptions regarding the adoption of HRD RNA and broader AI biomarkers could lead to a much more bullish story than the baseline view.

Check out 22 other fair value estimates for Tempus AI – Why the stock could be worth less than half its current price!

decide for yourself

Don’t just follow the ticker, dig deep into the data and truly build your own beliefs.

Interested in other options?

Our daily scan reveals stocks with breakout potential. Don’t miss this chance:

This article by Simply Wall St is general in nature. We provide commentary using only unbiased methodologies, based on historical data and analyst forecasts, and articles are not intended to be financial advice. This is not a recommendation to buy or sell any stock, and does not take into account your objectives or financial situation. We aim to provide long-term, focused analysis based on fundamental data. Note that our analysis may not factor in the latest announcements or qualitative material from price-sensitive companies. Simply Wall St has no position in any stocks mentioned.

Do you have feedback on this article? Interested in its content? Please contact us directly. Alternatively, email editorial-team@simplywallst.com.